|
Real-world survival outcomes and treatment patterns in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Results from the OREIOS study. |
|
|
No Relationships to Disclose |
|
Valeriy Vladimirovich Breder |
Honoraria - AstraZeneca; Bristol-Myers Squibb; Eisai; MSD Oncology; Roche; Takeda |
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Eisai; Roche; Sanofi/Regeneron; Takeda |
Travel, Accommodations, Expenses - Bayer; Bristol-Myers Squibb; Roche; Takeda |
|
|
Honoraria - AstraZeneca; Bayer; Bristol Myers Squibb Foundation; Eisai; Ipsen; Lilly; Merck; Ono Pharmaceutical; Roche |
Speakers' Bureau - AstraZeneca; Bayer; Bristol Myers Squibb Foundation; Eisai; Lilly; Merck; Ono Pharmaceutical; Roche |
Research Funding - AstraZeneca; Roche |
Travel, Accommodations, Expenses - Roche |
|
|
No Relationships to Disclose |
|
|
Honoraria - Abbvie; Arena Pharma; AstraZeneca; Bayer; Eva Pharma; Novartis; Pharco Pharmaceuticals |
|
|
Research Funding - AstraZeneca/MedImmune (Inst); Johnson & Johnson/Janssen (Inst); Novartis (Inst) |
|
|
No Relationships to Disclose |
|
|
|
|
|
|
|
|
Honoraria - Astellas Pharma; AstraZeneca; Bristol Myers Squibb Foundation; Daiichi Sankyo; Lilly; MSD; Novartis; Ono Pharmaceutical; Sanofi |
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Lilly; MSD; Novartis; Ono Pharmaceutical; Sanofi |